Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Anis Younes, Joshua Brody, Cecilia Carpio, Armando Lopez-Guillermo, Dina Ben-Yehuda, Berhan Ferhanoglu, Arnon Nagler, Muhit Ozcan, Irit Avivi, Francesc Bosch, Maria Dolores Caballero Barrigon, Andrzej Hellmann, Bryone Kuss, David Ma, Faith Demirkan, Münci Yağci, Netanel Horowitz , Paula Marlton, Raul Cordoba, Tomasz WrobeDaniela Buglio, Michael Streit, Brendan Hodkinson, Michael Schaffer, John Alvarez, Rob Ceulemans, Sriram Balasubramanian, Jan de Jong, Shean-Sheng Wang , Nele Fourneau, Wojciech Jurczak

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)

Fingerprint Dive into the research topics of 'Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study'. Together they form a unique fingerprint.

Medicine & Life Sciences